Target ALS

Following the loss of her mother to ALS, Brooke Emmerich and her theater family are paying tribute & raising funds with a cabaret show. Get a ticket: ow.ly/WUhY50Z2rGF Chip in to Brooke's page: ow.ly/XNTc50Z2rGE Start your own fundraiser: ow.ly/IvNL50Z2rGG

Today, we're proud to announce that Toby Ferguson, MD, PhD and Joe Lewcock, PhD have joined the Target ALS Board of Directors. They've each spent careers proving ALS can be moved from intractable to treatable. Now they're bringing their expertise to our governance and strategy.

Zero FDA-approved treatments exist to stop ALS. Current therapies only offer modest benefit or apply to a narrow group of those living with ALS. This is the gap we must close. We’re #ALLIN until zero becomes many. Until #EveryoneLives. Join us: ow.ly/xw0250Z0m2U

When the people building the treatments are as All In as the people waiting for them, that's when things change. Damon Wang, Co-Founder and CEO of NuCyRNA, shares what he’s #ALLIN for. Join him: ow.ly/A17n50YZLWx #EveryoneLives #ALSAwarenessMonth #ALSResearch #ALS

The most powerful voices in the fight against #ALS are the people living with this disease every day, who refuse to be silent about it. Swipe to see what it means to be #ALLIN. What are you All In for? Share your story: ow.ly/RAHL50YZLl5 #EveryoneLives #ALSAwarenessMonth

At Target ALS: We FUND research through grants. We ENABLE the best ideas with open-access, no-strings-attached resources. We CONDUCT our own research through the ALS Global Research Initiative. Give to power a model built for speed and scale. Be All In: ow.ly/IByC50YYtZA

At this year’s Annual Meeting, Target ALS Board Member and founding donor, Alisa Doctoroff, shared a powerful message of grief and hope with some of the world's leading ALS researchers, clinicians, and scientists. Watch now: ow.ly/CFZf50YZn5e #EveryoneLives

When it comes to ending ALS, @BloombergDotOrg is #ALLIN. Their support of Target ALS powers a bold, open-science approach to defeating this devastating disease. Together, we're proving that collaboration accelerates breakthroughs. See their impact: ow.ly/wxpk50YYtNE

33,000 people in the U.S. live with ALS today and the number is growing. Behind every data point is a person, a family, a future being rewritten. That's why we're All In for research that moves faster than this disease. Go #ALLIN for #ALSResearch: ow.ly/PHaV50YYtKM

As Scientific Coordinator of the Molecular Pathology Group at @ICGEB, Dr. Buratti has spent his career advancing the science behind ALS, and he believes the field is at an inflection point. 🔗 targetals.org/all-in/

Great to connect with the team from @EliLillyandCo this week. Lilly has been at the forefront of turning science into treatments that reach those who need it most, and their presence here reflects a shared urgency to do the same for ALS. Grateful for their sponsorship!

This past weekend, Team Target ALS biked through all five boroughs of New York City in the Five Boro Bike Tour, each committed to raising $1,000 for Target ALS. And they rode every mile of it #ALLIN for ALS research. Go All In: targetals.org/all-in/

The room is full of people who believe ALS is a solvable disease, and nights like this remind us why. Thank you to @bmsnews for bringing us together at the Target ALS Annual Meeting reception. The connections made here move science forward. #BMS #AnnualMeeting

Thank you to @Alnylam for being a silver-level sponsor for the Target ALS Annual Meeting! As the pioneer of the RNA interference (RNAi) revolution, Alnylam is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease.

Fueled and ready for the afternoon sessions, thanks to ShionogiUS. Their commitment to developing innovative medicines for rare diseases helps make gatherings like this possible, where the brightest minds in ALS research come together to accelerate progress.

Thanks to @ShionogiUS for sponsoring lunch at the Annual Meeting. Shionogi's rare disease franchise includes an approved ALS therapy plus clinical programs in Fragile X, Jordan's, and Pompe — advancing innovative medicines for communities with unmet need.

Every person at our Annual Meeting is All In on ALS research. Join them: targetals.org/all-in/ #ALSAwarenessMonth #EveryoneLives #ALS #ALSresearch

Acelot is sponsoring the official Target ALS Annual Meeting playlist, because great science deserves great music. Acelot is developing ACE-2223, a first-in-class oral small molecule designed to address misfolded TDP-43, a hallmark of sporadic ALS. open.spotify.com/playlist/20Wqw…

Thank you to @Acelot for keeping us caffeinated at the Target ALS Annual Meeting. Acelot is advancing ACE-2223, targeting misfolded TDP-43 in sporadic ALS, with a Phase Ia healthy volunteer trial underway. Between the coffee and the cutting-edge research, we're energized.

Thank you to @bmsnews for sponsoring last night's reception at the Target ALS Annual Meeting. BMS is a global biopharmaceutical company developing medicines that help patients prevail over serious diseases, including those affecting the nervous system.